Internal Medicine, Endocrinology, Diabetes, & Metabolism · Staten Island, NY
NPI
1477664134
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
774 Manor Rd, Suite 208
Staten Island, NY, 10314
Phone (718) 273-5522
Groups this clinician bills Medicare through
Medicare paid, 2024
$157K
1,731 services
Medicare patients, 2024
751
Average age 73
Drug cost, 2024
$6.2M
15,746 prescriptions
Company payments, 2025
$145
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Seshadri Das was code 99214 (office e&m - established), 1,469 times for 731 patients. In total Seshadri Das billed 1,731 services in 8 codes, and Medicare paid $157K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-04-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,469 | 731 | $98.46 | $145K |
| 99215 Office E&M - Established | Office | 38 | 37 | $124.93 | $4,747 |
| 99213 Office E&M - Established | Office | 19 | 18 | $47.35 | $900 |
| 99204 Office E&M - New | Office | 17 | 17 | $134.27 | $2,283 |
By year: 2022 $224K for 2,131 services; 2023 $220K for 2,052 services; 2024 $157K for 1,731 services.
Medicare prescription drug claims, 2024
In 2024, the drug Seshadri Das prescribed most often to Medicare patients was Atorvastatin Calcium, with 1,015 prescriptions and refills. In total Seshadri Das wrote 15,746 Medicare prescriptions that cost $6.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 1,015 | 2,615 | 318 | $13K |
| Jardiance Empagliflozin | 940 | 2,307 | 294 | $1.3M |
| Metformin Hcl Generic | 784 | 2,123 | 246 | $6,133 |
| Rosuvastatin Calcium Generic | 735 | 2,075 | 251 | $12K |
| Levothyroxine Sodium Generic | 665 | 1,761 | 187 | $7,184 |
| Ezetimibe Generic | 608 | 1,553 | 187 | $13K |
| Mounjaro Tirzepatide | 469 | 807 | 112 | $848K |
| Synthroid Levothyroxine Sodium | 466 | 1,212 | 120 | $41K |
| Losartan Potassium Generic | 458 | 1,306 | 162 | $4,604 |
| Ozempic Semaglutide | 443 | 878 | 121 | $831K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 345 | 912 | 147 | $43K |
| Simvastatin Generic | 302 | 718 | 87 | $2,182 |
| Glimepiride Generic | 267 | 707 | 85 | $2,721 |
| Trulicity Dulaglutide | 262 | 561 | 74 | $547K |
| Novolog Flexpen Insulin Aspart | 260 | 620 | 94 | $68K |
Brand drugs: 5,544 claims; generic drugs: 9,212 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Seshadri Das $145 ($145 in general payments such as food, travel and fees) from 1 company. The largest payer was Insulet Corporation with $145.
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation PODD | 10 | $145 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.